A Phase 1 interventional study of Donanemab and Placebo in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the safety and tolerability of donanemab (LY3002813) when administered as single dose in healthy Chinese participants. The study will also assess how fast donanemab gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 85 days.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 350 mg Donanemab dose administered intravenously (IV) on Day 1.
Drug: Donanemab
Single 700 mg Donanemab dose administered IV on Day 1.
Drug: Donanemab
Single 1400 mg Donanemab dose administered IV on Day 1.
Drug: Donanemab
Single placebo dose administered IV on Day 1.
Drug: Placebo
Administered IV.
Also known as: LY3002813
Administered IV.
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.
Time frame: Baseline up to Day 85
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Donanemab
PK: Cmax of Donanemab
Time frame: Predose, Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57 and 85 postdose
PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Donanemab
PK: AUC\[0-∞\] of Donanemab
Time frame: Predose, Days 2, 3, 4, 5, 8, 15, 22, 29, 43, 57 and 85 postdose
| Milestone | Placebo | 350 Milligram (mg) Donanemab | 700 mg Donanemab | 1400 mg Donanemab |
|---|---|---|---|---|
| Started | 6 | 10 | 10 | 10 |
| Received at least 1 dose of study drug | 6 | 10 | 10 | 10 |
| Completed | 6 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is located in the Reported Adverse Event module. Drug related TEAEs are any untoward medical occurrences that either occurs postdose or presents prior to dosing yet becomes more severe postdose, and in the opinion of the investigator is possibly related to study drug.
| participants | Placebo | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab |
|---|---|---|---|---|
| Treatment-emergent Adverse Events | 1 | 2 | 0 | 0 |
| Serious Adverse Events | 0 | 0 | 0 | 0 |
PK: Cmax of Donanemab
| microgram per milliliter (μg/mL) | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab |
|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Donanemab | 119 ± 13 | 236 ± 9 | 539 ± 30 |
PK: AUC\[0-∞\] of Donanemab
| microgram * hour/milliliter (μg.h/mL) | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab |
|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Donanemab | 9050 ± 23 | 22600 ± 17 | 53100 ± 27 |
Collected over Baseline up to 85 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| 350 Milligrams (mg) Donanemab | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| 700 mg Donanemab | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| 1400 mg Donanemab | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Event | Placebo | 350 Milligrams (mg) Donanemab | 700 mg Donanemab | 1400 mg Donanemab |
|---|---|---|---|---|
| Blood uric acid increasedInvestigations | 3/6 | 1/10 | 1/10 | 0/10 |
| Asymptomatic COVID-19Infections and infestations | 1/6 | 1/10 | 1/10 | 3/10 |
| COVID-19Infections and infestations | 0/6 | 0/10 | 2/10 | 1/10 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 0/10 | 0/10 | 1/10 |
| Blood creatine phosphokinase increasedInvestigations | 1/6 | 1/10 | 1/10 | 0/10 |
| Blood urea increasedInvestigations | 1/6 | 0/10 | 0/10 | 0/10 |
| DizzinessNervous system disorders | 1/6 | 0/10 | 0/10 | 0/10 |
| Allergy to arthropod biteImmune system disorders | 0/6 | 1/10 | 0/10 | 0/10 |
| Otitis mediaInfections and infestations | 0/6 | 0/10 | 1/10 | 0/10 |
| Alanine aminotransferase increasedInvestigations | 0/6 | 1/10 | 0/10 | 0/10 |
All randomized participants.
| Age, Continuous(years) | Placebo | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab | Total |
|---|---|---|---|---|---|
| Mean | 27.0 ± 7.0 | 28.1 ± 6.2 | 32.8 ± 4.5 | 27.9 ± 5.8 | 29.2 ± 6.0 |
| Sex: Female, Male(Participants) | Placebo | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 10 | 10 | 10 | 36 |
| Race (NIH/OMB)(Participants) | Placebo | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 10 | 10 | 10 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | 350 mg Donanemab | 700 mg Donanemab | 1400 mg Donanemab | Total |
|---|---|---|---|---|---|
| China | 6 | 10 | 10 | 10 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Jan 2023, 3 months.
Results were first posted in Oct 2024, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donanemab